PHILADELPHIA and OXFORD, United Kingdom, May 26, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP ), a leader in T-cell therapy to treat cancer, today announced an oral presentation, as well as four trials in progress posters, at the 2017 ASCO annual meeting in Chicago, Illinois on June 2 through June 6, 2017.
During an oral presentation scheduled for 1:15-1:27 PM CDT on June 5 th , Dr. Sandra P. D’Angelo of the Memorial Sloan Kettering Cancer Center will present a full update on Cohorts 1, 2, 3, and 4 from Adaptimmune’s ongoing study of NY-ESO SPEAR T-cells in patients with synovial sarcoma.
The Company will host a webinar / teleconference on June 6 th from 8:00–9:00 AM EDT (1:00 -2:00 PM BST) to discuss the updated synovial sarcoma clinical data. Call in details and the webinar link will be made available in the Investors section of Adaptimmune’s website ( http://www.adaptimmune.com ).
The four trials in progress posters will summarize the study designs for Adaptimmune’s ongoing NY‑ESO trials in myxoid/round cell liposarcoma (MRCLS), ovarian cancer, and non-small cell lung cancer (NSCLC); the Company’s ongoing MAGE-A10 trial in NSCLC, and its MAGE-A10 triple tumor study in patients with head and neck, melanoma, or urothelial “bladder” tumors.
Adaptimmune will also host a corporate exhibition booth in the Oncology Professionals Hall (Booth #5031).
Details regarding the oral presentation and the four trials in progress posters are as follows:
Oral Presentation: Monday, June 5, 2017 Session: Developmental Therapeutics—Immunotherapy
• Abstract ID: 3000 — Title: “Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1 c259t in HLA-A2 + patients with synovial sarcoma (NCT01343043)” — Presentation Time: 1:15-1:27 PM CDT — Location: Hall D1
Trials in Progress Posters: Monday, June 5, 2017 Session: Developmental Therapeutics—Immunotherapy Presentation Time: 8:00-11:30 AM CDT Location: Hall A
• Abstract ID: TPS3094 — Poster Board #: 187b — Title: “A phase I/IIa, open-label, clinical trial evaluating the safety and efficacy of autologous T-cells expressing enhanced T-cell receptors (TCRs) specific for NY-ESO-1 in patients with recurrent or treatment refractory ovarian cancer (NCT01567891)”
• Abstract ID: TPS3097 — Poster Board #: 189a — Title: “A pilot study of NY-ESO-1 c259 T-cells in subjects with advanced myxoid/round cell liposarcoma (NCT02992743)” • Abstract ID: TPS3096 — Poster Board #: 188b — Title: “Two phase I/II open-label clinical trials evaluating the safety and efficacy of autologous T‑cells expressing enhanced TCRs specific for NY-ESO-1 or MAGE-A10 in subjects with stage IIIb or stage IV non-small cell lung cancer (NCT02588612/NCT02592577)”
• Abstract ID: TPS3098 — Poster Board #: 189b — Title: “A phase I single-arm, open-label clinical trial evaluating safety of MAGE-A10 c796T in subjects with advanced or metastatic head and neck, melanoma, or urothelial tumors (NCT02989064)”
About Adaptimmune Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune has a number of proprietary clinical programs, and is also developing its NY-ESO SPEAR T-cell program under a strategic collaboration and licensing agreement with GlaxoSmithKline. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit http://www.adaptimmune.com
Forward-Looking Statements This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 10, 2017, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contacts Investor Relations Juli P. Miller, Ph.D. T: (215) 825-9310 E: juli.miller@adaptimmune.com Media Relations Margaret Henry T: +44 (0)1235 430036 Cell: +44 (0)7710 304249 E: margaret.henry@adaptimmune.com
